The Cost-Effectiveness OF Canagliflozin (Cana) Versus Dapagliflozin (Dapa) In Patients With Type 2 Diabetes Mellitus (T2dm) With Inadequate Control On Metformin (Met) Monotherapy In The United Kingdom
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.694
https://www.valueinhealthjournal.com/article/S1098-3015(14)02624-2/fulltext
Title :
The Cost-Effectiveness OF Canagliflozin (Cana) Versus Dapagliflozin (Dapa) In Patients With Type 2 Diabetes Mellitus (T2dm) With Inadequate Control On Metformin (Met) Monotherapy In The United Kingdom
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)02624-2&doi=10.1016/j.jval.2014.08.694
First page :
A344
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
116